Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2022. During the reporting period, the company upheld the concept of original innovation and global innovation, and achieved multiple milestones in commercialization, clinical development, and Read More ›

Ascentage Pharma (6855.HK) today announced that the latest results from three preclinical studies of the company’s novel third-generation BCR-ABL inhibitor olverembatinib (HQP1351) and two key assets of Ascentage Pharma’s apoptosis-targeting pipeline, the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin (APG-115), have been selected for presentations at the 2023 American Association of Cancer Research Annual Meeting (AACR 2023). These Read More ›

Ascentage Pharma and Innovent Biologics today announced that the novel drug olverembatinib has been included into the China 2022 National Reimbursement Drug List（NRDL), for the treatment of T315I-mutant chronic-phase chronic myeloid leukemia (CML-CP) and accelerated-phase CML (CML-AP). The new version of the NRDL will take effect on Mar 1st, 2023. Developed by Ascentage Pharma with Read More ›

Ascentage Pharma (6855.HK) today announced that Dr. Dajun Yang, the company’s Chairman and CEO, has delivered a presentation at the 41st Annual J.P. Morgan Healthcare Conference showcasing the progress Ascentage Pharma has made with its global innovation strategies and rapid transition from a biotech to a full-fledged biopharmaceutical company. Accelerated Commercialization of Its First Approved Read More ›

Ascentage Pharma (6855.HK) today announced that it has delivered two Oral Presentations on Chinese studies of the company’s novel drug candidate olverembatinib (HQP1351) at the American Society of Hematology (ASH) 64th Annual Meeting and Exposition (New Orleans, LA). These two Oral Presentations featured Phase II results and 5-year follow-up data of olverembatinib. Prof. Xiaojun Huang Read More ›

Ascentage Pharma (6855.HK) today announced that it has released preliminary results of olverembatinib (HQP1351) in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), in an Oral Presentation at the American Society of Hematology (ASH) 64th Annual Meeting and Exposition (New Orleans, LA), marking the first data readout from the Read More ›

Ascentage Pharma (6855.HK)  today announced that it has released preliminary results from a global Phase II study of lisaftoclax (APG-2575), a key member of the company’s apoptosis-targeting pipeline, as a monotherapy or in combination with CALQUENCE® (acalabrutinib) or rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL), in an oral Read More ›

Ascentage Pharma (6855.HK) today announced that its novel inhibitor of the embryonic ectoderm development (EED) protein, APG-5918, has been approved by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) to enter a Phase I study in patients with advanced solid tumors or hematologic malignancies. Following the recent clearance for the Read More ›

Ascentage Pharma (6855.HK) today announced that it has released results from a Phase I study of the investigational inhibitor of apoptosis protein (IAP) antagonist APG-1387 in Chinese patients with chronic hepatitis B (CHB), in an oral presentation at the 73rd American Association for the Study of Liver Diseases Annual Meeting (AASLD 2022). This is the Read More ›

Ascentage Pharma today announced that the updated results from three studies of the company’s novel drug candidate, olverembatinib (HQP1351), have been selected for oral presentations at the 64th American Society of Hematology (ASH) Annual Meeting. This is the fifth consecutive year in which studies of olverembatinib were selected for oral presentations at the ASH Annual Read More ›